

# 22.

Bölüm

## GÖĞÜS HASTALIKLARI VE COVID-19

Savaş GEGİN<sup>1</sup>

1. COVID-19 hastalığının akciğere etkileri nelerdir?
2. Astım hastasıyım, pandemide ne yapmalıyım?
3. KOAH hastasıyım, pandemide ne yapmalıyım?
4. Akciğer Kanseri hastasıyım, pandemide ne yapmalıyım?

### GİRİŞ

Pnömoni salgının hızla dünyaya yayılması nedeni ile Dünya Sağlık Örgütü (DSÖ) 30 Ocak'ta "uluslararası boyutta halk sağlığı acil durumu" ve 11 Mart'ta pandemi (küresel salgın) olarak ilan etti. Hastalığın adı COVID-19 olarak tımlandı. Salgın halen kontrol altına alınamamış olup tüm dünyada hızla yayılmaktadır (1-4).

### BULAŞMA ŞEKLİ

Hastalığın bulaşma yolu diğer viral enfeksiyonlarla benzer şekildedir. Damlacık yolu ve temas ile olmaktadır. Hasta bireylerin öksürmesi, hapşırması ve konuşması ile yayılması, salgıların direkt mukozaya temas etmesi sonucu ve havadaki damlacıkların yüzeye yapışması, el ile bu yüzeylere temas sonrası ağız, burun ve göz mukozasına dokunarak indirekt yolla bulaş olmaktadır. Damlacık yolu ile bulaşma 1,5-2 metrelük mesafeden olabilmektedir. Virüsün bulaşmasında hasta bireyler ile temas süresi ve yoğunluğu önemlidir. Bulaşmayı etkileyen diğer fak-

<sup>1</sup> Uzm. Dr. Savaş GEGİN, Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi  
Göğüs Hastalıkları Servisi geginn@hotmail.com

## KAYNAKLAR

1. Wuhan Municipal Health Commission (2019) Report of clustering pneumonia of unknown etiology in Wuhan City. <http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989> [in Chinese] (accessed 10 April 2020).)
2. World Health Organization (2020) Novel coronavirus (2019-nCoV). Situation Report 22. 11 February 2020. [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1\\_2](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2) (accessed 10 April 2020).
3. World Health Organization (2020) Novel coronavirus (2019-nCoV). Situation Report 11. 31 January 2020. [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4) (accessed 10 April 2020).
4. World Health Organization (2020) Novel coronavirus (2019-nCoV). Situation Report. 11 March 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-March-2020> (accessed 10 April 2020).)
5. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ. Bilim Kurulu Çalışması, T.C. Sağlık Bakanlığı 12 Nisan 2020, Ankara.
6. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* 2020;24:91–98.
7. Herper .C. temuz 2020 Bursa Tabip Odası sürekli Tip eğitimi Pandemi Kitabı multidisipliner COVID -19 , Bölüm 10; COVID-19 ve Akciğer s.157-183, Bursa Tabip Odası Yayınları
8. Zhou P, Yang XL, Wang XG, Hu B, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020 Mar; 579 (7798): 270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.)
9. Türkiye Solunum Araştırmaları Derneği Coranavirüs hastalığı (COVID-19) ve Akciğer: *Göğüs Hastalıkları Uzmanlarının Bilmesi Gerekenler*, Eurasian Journal of Pulmonology ,2020 Aust. Volum 22 ,page1-104
10. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized BÖLÜM 10 177 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020
11. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review [published online ahead of print, 2020 Mar 19]. *Eur Radiol.* 2020;1-9.
12. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. *Eur Radiol.* 2020;30(6):3306-3309.
13. Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. *Radiology* 2020;295:22–23.
14. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: Relationship to negative RT-PCR testing. *Radiology* 2020;200343.
15. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020;10.1111/all.14238. 94
16. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. *Allergy* 2020;10.1111/all.14289.
17. Global Initiatives for Asthma. Global Strategy for Asthma Management and Prevention 2020, [www.ginasthma.org](http://www.ginasthma.org)
18. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: Pandemic contingency planning for the allergy and immunology clinic. *J Allergy Clin Immunol Pract* 2020;S2213-2198(20)30253-1.
19. Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. ARIA-MASK study group. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAA-CI statement. *Allergy* 2020;10.1111/all.14302.
20. Kelly KJ, Sussman G. Latex allergy: Where are we now and how did we get there? *J Allergy*

- Clin Immunol Pract 2017;5:1212-1216.
21. Global Strategy for Diagnosis, Management and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Diseases (GOLD). 2020 report. Available from: <https://goldcopd.org/gold-reports/> [Access: 01.01.2020].
  22. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist 2020; 21:22–275
  23. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;10.1001/jama.2020.4683.
  24. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) COVID-19 Guidance, 2020. <https://goldcopd.org/gold-COVID-19-guidance/>
  25. NICE guideline. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. Published date: 03 April 2020
  26. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. IndacaterolGlycopryronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016;374:2222–2234.
  27. Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ March 30, 2020 192 (13) E346.
  28. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–337.
  29. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease. JAMA 2020;10.1001/jama.2020.2648.
  30. Balestra R, Selvaraju A, Benzaquen S, Zander DS. Pneumonic-type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy. Respirol Case Rep 2017;5:e00222.
  31. Wei J, Xu H, Xiong J, Shen Q, Fan B, Ye C, et al. 2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings. Korean J Radiol 2020;21:501–504.
  32. Shereen NG, Salman D. Delivering chemotherapy at home: How much do we know? Br J Community Nurs 2019;24:482–484.
  33. You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol 2020:S1470-2045(20)30204-7.
  34. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ. 2 NİSAN 2020. [https://COVID19bilgi.saglik.gov.tr/depo/rehberler/COVID-19\\_Rehberi.pdf](https://COVID19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf)
  35. Akyol, M., & KÖMÜRCÜOĞLU, B. COVID-19 Pandemi Döneminde Akciğer Kanseri Yönetimi. *İzmir Göğüs Hastanesi Dergisi*, 34(2), 55-61.